Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
Study Acronym: CANVAS
Study Information
Alliance Study ID: AFT-28
NCT Study ID (ClinicalTrials.gov): NCT02744092
Disease or Cancer Type: Other Cancer
Alliance Study Chair: Jean Connors, MD; Deborah Schrag, MD MPH
Status: COMPLETED
Study Description
The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients. The intervention strategy is Direct Oral AntiCoagulants (DOAC) therapy with edoxaban, apixaban, rivaroxaban, or dabigatran. The comparator is low molecular weight heparin (LMWH) alone or with warfarin. The information gained will empower cancer patients and physicians to make more informed choices about anticoagulation strategies to manage VTE.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information